| Literature DB >> 20831794 |
Pengfei Zhu1, Yanxia Ning, Liangqing Yao, Mo Chen, Congjian Xu.
Abstract
BACKGROUND: Epithelial ovarian cancer is one of the most malignant cancers in women because metastasis occurs in the most of patients by the time of diagnosis. Cancer cells have strong capacity to form angiogenesis or vasculogenic mimicry, which plays the major role in its malignant phenotype. Vasculogenic mimicry might contribute to the failure of the angiogenesis-targeted therapy strategies. Under the microenvironment of the tumor, hypoxia is the most common phenomena because of the vast energy and oxygen consuming. In the present study, the endothelial-like cells induced by hypoxia from SKOV-3 and ES-2 ovarian cancer cells were harvested to investigate the changes in their biological behaviors.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20831794 PMCID: PMC2944817 DOI: 10.1186/1756-9966-29-124
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
The sequences of the primers used in the experiment
| Gene | Sense | Antisense | Product (bps) |
|---|---|---|---|
| HIF1α | TGCACAGGCCACATTCACGT | GTTCACAAATCAGCACCAAGC | 97 |
| Flk-1 | ACAGTGGTATGGTTCTTGCCTCA | GTAGCCGCTTGTCTGGTTTGA | 140 |
| VEGF | TCACCAAGGCCAGCACATAG | GGGAACGCTCCAGGACTTAT | 166 |
| Cyclin D1 | GATGCCAACCTCCTCAACGAC | CTCCTCGCACTTCTGTTCCTC | 171 |
| V-src | CACTCGCTCAGCACAGGACAG | AGAGGCAGTAGGCACCTTTCG | 196 |
| P53 | GCTGCTCAGATAGCGATGGTC | CTCCCAGGACAGGCACAAACA | 298 |
| β-actin | CCTGTACGCCAACACAGTGC | ATACTCCTGCTTGCTGATCC | 211 |
Figure 1The morphology of the ELs from ovarian cancer induced by hypoxia and microdissected by LCM. The ovarian cancer cells were cultured in 3-dimisonal Matrigel system on EVA membrane under hypoxia for 7 d before harvest. The pictures were taken under the light microscope. A and B. The original and after microdissected by LCM of the single cell. C and D. The original and after microdissected by LCM of the grouped cells. Magnification X200. Arrow: The morphology of the cells after microdissection.
Figure 2The proliferation, cell cycle, apoptosis, invasion of SKOV-3, ES-2 and HUVEC cells induced by hypoxia. The SKOV-3, ES-2 and HUVEC cells were cultured for 3 or 7 d in normoxia or hypoxia conditions before proliferation, cell cycle (S-phage), apopotosis and invasion detected by MTT, FCM (for cell cycle and apoptosis) and Transwell as shown in methods. A. The proliferation of three cells by MTT. B. The S-phase ratio in three cells by FCM. C. The apoptosis of three cells detected by FCM. D and E. The numbers of cells invasion through the membrane indicated by Transwell after incubated for 3 days (D) or 7 days (E). Data were shown in Mean ± S.D. from three separate experiments with the similar result. * and ** indicates P < 0.05 and P < 0.01 vs. Normoxia.
Figure 3The genes expression in SKOV-3, ES-2, ELs from cancer cells and HUVEC induced by hypoxia. The SKOV-3, ES-2 and HUVEC cells were cultured for 7 d in normoxia or hypoxia conditions before harvested for the expression of HIF-1a, VEGF, Flk-1, CyclinD1, p53 and V-src genes detected by Real-time PCR. A. The genes expression in SKOV-3 and relative cells by Real-time PCR. B. The genes expression in ES-2 and relative cells by Real-time PCR. SKOV-3 EL: the endothelial-like cells induced from SKOV-3 cells; SKOV-3+Si: the SKOV-3 cells treated by Sirolimus under hypoxia; ES-2 EL: the endothelial-like cells induced from ES-2 cells; ES-2+Si: the ES-2 cells treated by Sirolimus under hypoxia; *, ^, and & indicates that P < 0.05 vs.HUVEC, SKOV-3 (or ES-2) and SKOV-3+Si (or ES-2+Si); **, ^^, and && indicates that P < 0.01 vs.HUVEC, SKOV-3 (or ES-2) and SKOV-3+Si (or ES-2+Si).
The activity of telomerase in different cells
| CELLS | RESULT |
|---|---|
| HUVEC | - |
| SKOV-3 | + |
| SKOV-3 EL | + |
| SKOV-3+Si | + |
| ES-2 | + |
| ES-2 EL | - |
| ES-2+Si | - |
SKOV-3 EL: the endothelial-like cells induced from SKOV-3 cells; SKOV-3+Si: the SKOV-3 cells treated by Sirolimus under hypoxia; ES-2 EL: the endothelial-like cells induced from ES-2 cells; ES-2+Si: the ES-2 cells treated by Sirolimus under hypoxia.